424B3424B3
Jun 18, 2026Final prospectus0001554855-26-001370
All companies
Trade Trinity Biotech PlcTrinity Biotech registers 675M shares for resale | TRIB SEC Filing - Form F-1/A Trinity Biotech registers 35.28M ADSs for resale | TRIB SEC Filing - Form F-1
TR
Trinity Biotech Plc
TRIBPublic
PublicUnited States(Nasdaq)Best valuation $11.79M1 market
Public listing
Listed· Nasdaq· Listing market: United StatesListing date
Not available
Offer price
Not available
Shares offered
Not available
Offering proceeds
Not available
Sources: sec-edgar, sec-harvest, nasdaq
IPO Calendar · NasdaqIPO
TRIBPrice
$0.5820
24h
+0.34%
Valuation
$11.79M
24h volume
$78.66K
Type
IPO
Trade Trinity Biotech PlcNow trading publicly. Buy via a broker — opens in a new tab.
IPO Calendar · updated 2h ago
About Trinity Biotech Plc
Trinity Biotech Plc is its products are used to detect infectious diseases and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood.
What the company does
- the company sell its products directly in the United States and Brazil and in the United Kingdom, Germany and France and through a network of international distributors and strategic partners in approximately 100 countries worldwide....
- Develops healthcare products, therapies, devices, or services where clinical evidence and regulatory execution are central to the business.
- Operates in a market shaped by product differentiation, development timelines, reimbursement or customer adoption, and disciplined capital allocation.
Business profile
Trinity Biotech Plc belongs to the healthcare and life-sciences market, where product evidence, regulatory pathways, customer adoption, and funding discipline shape long-term outcomes.
SEC IPO filings
Final prospectusEDGAR filings resolved from TRIB / CIK 0000888721.
424B3424B3
Jun 15, 2026Final prospectus0001554855-26-001334
Jun 10, 2026Effective9999999995-26-001939
RWFORM RW
Jun 3, 2026Withdrawn0001554855-26-001226
F-1/AFORM F-1/A
Jun 3, 2026Amended0001554855-26-001225
424B3424B3
May 26, 2026Final prospectus0001554855-26-001128
May 22, 2026Effective9999999995-26-001746
424B3424B3
Mar 10, 2026Final prospectus0001178913-26-000806
424B3424B3
Mar 10, 2026Final prospectus0001178913-26-000804
424B3424B3
Mar 4, 2026Final prospectus0001178913-26-000700
Mar 3, 2026Effective9999999995-26-000713
CORRESPfilename1.htm
Feb 27, 2026SEC correspondence0001178913-26-000656
Latest Trinity Biotech Plc IPO news
Recent sourced articles classified for IPO relevance, with platform-access noise filtered out where possible.
StockTitanJun 3, 2026IPO filing
Company filed a Form F-1/A (secondary offering/resale registration) tied to its Standby Equity Purchase Agreement; strong IPO-related SEC registration context for TRIB itself, not a platform.
StockTitanFeb 25, 2026IPO filing
Company’s Form F-1 registration for resale (ADSs) under its equity purchase arrangement; TRIB-specific SEC IPO-registration context.
Trinity Biotech Plc IPO — frequently asked questions
- When did Trinity Biotech Plc go public?
- Trinity Biotech Plc has already gone public and now trades publicly on Nasdaq under the ticker TRIB.
- Can I buy Trinity Biotech Plc stock?
- Yes — Trinity Biotech Plc is publicly traded on Nasdaq as TRIB. You can follow its live price, valuation and post-IPO performance above.
- What is Trinity Biotech Plc's valuation?
- Trinity Biotech Plc's most recent valuation tracked here is $11.79M, derived from live market prices.